Market news

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

REDWOOD CITY, Calif., September 23, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the retirement of Sean Maduck, President of the company’s Endocrinology division. Justin Gunn will succeed Mr. Maduck and will fully assume his new responsibilities starting Octobe

Corcept Therapeutics (CORT) drew fresh attention after the European Medicines Agency’s CHMP backed approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, following positive Phase 2 and Phase 3 ROSELLA data. Corcept Therapeutics’ latest CHMP backing lands after a powerful run in the share price, with a 90-day share price return of 44.07% and a year to date share price return of 207.60%, while the 5-year total shareholder return of 487.23% points to momentum that...

On September 18, Corcept Therapeutics (NASDAQ:CORT) said Europe’s drug regulator recommended approval for the cancer therapy that has already earned a spot in US cancer treatment guidelines. The Committee for Medicinal Products for Human Use backed relacorilant, sold in the US as Lifyorli, for use alongside the chemotherapy drug nab-paclitaxel in patients with platinum-resistant ovarian […]

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

Tipranks Press Release.

Corcept Therapeutics (CORT) said Friday the European Medicines Agency's Committee for Medicinal Prod

REDWOOD CITY, Calif., September 18, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined w

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

Roberto Wandenkolk Vieira, President, Oncology, on September 01, 2026, sold 58,333 shares in Corcept

Sean Maduck, President, Corcept Endocrinology, on September 01, 2026, sold 25,000 shares in Corcept

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Let’s dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season.

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its peers.

Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year. CORT’s fundamentals are robust with revenue and earnings both projected to grow this year. Technical indicators remain bullish with a 100% “Buy” opinion from Barchart. Analyst sentiment is mixed —ratings range from “Strong...

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing’s syndrome.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Revenue surged 32% to $256.1 million, driven by strong Cushing's syndrome sales and a successful Lifyorli launch, as the company raises full-year guidance.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?